News and Trends 7 Feb 2020 EU Project Set up to Fight Alzheimer’s Disease with Lasers A project has launched with a €3.6M grant to treat neurological conditions such as Alzheimer’s and Huntington’s disease by making brain cells controllable with red light. There are currently no treatments approved that can slow the progression of neurodegenerative conditions, including Alzheimer’s and Huntington’s disease. Treatments approved to alleviate the symptoms only help a small […] February 7, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Feb 2020 Swiss Biotech Raises €16M to Treat Autism Spectrum Disorder Stalicla has bagged €16.3M in a Series A round to test drugs repurposed using AI for the treatment of autism spectrum disorder in phase I. The round consists of a recent €7M (CHF 7.7M) closing and an initial first tranche of €9.3M (CHF 10M) raised last year. The investors in the latest closing were not […] February 4, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 9 Dec 2019 As Big Pharma Abandons Neuroscience, Can Biotech Provide Answers? With big pharma exiting the neurology space in droves, biotech innovation might be the key to bring about a much-needed shift. At the Bio-Europe conference in Hamburg last month, experts weighed in on the challenges and future of neuroscience. Over the last decade, big pharma has become disillusioned with neuroscience research. Eli Lilly, Amgen, Pfizer, […] December 9, 2019 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2019 Orchard’s Gene Therapy Improves Children’s Motor Ability Orchard Therapeutics’ gene therapy for metachromatic leukodystrophy (MLD) resulted in motor ability improvements more than six times over the target endpoint, according to data released at a recent symposium. “Metachromatic leukodystrophy is a rare disease that affects the brain,” explained Mark Rothera, CEO of Orchard Therapeutics. “Kids born with MLD lose motor function very fast […] September 5, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Startup Scout 31 May 2019 This Biotech Treats a Neurological Autoimmune Disorder Using DNA We’re jumping into Poland this week. Pure Biologics is a biotech based in Wrocław developing DNA molecules that could treat the incurable neurological condition Devic’s disease with fewer side effects than existing treatments. Mission: To develop a treatment that makes an existing treatment for Devic’s disease, plasmapheresis, more targeted and with fewer side effects than […] May 31, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Mar 2019 Swiss Biotech Raises €20M to Develop Decoy Drugs in Autoimmune Disease The biotech Polyneuron has raised a Series A round of €20.1M (CHF 22.5M) to start human testing with a treatment for a rare autoimmune disease. Based in Basel, Polyneuron is developing drugs to treat anti-MAG peripheral neuropathy. This debilitating disease is caused by the immune system producing autoantibodies that attack nerve support cells, which stops […] March 28, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Feb 2018 Early Autism Diagnosis Could be Possible With New Blood and Urine Tests The detection of damaged proteins in blood and urine tests could help to diagnose autism quicker so that children can be given appropriate treatment. Researchers at the University of Warwick have developed new blood and urine tests that detect damaged proteins, which are associated with autism spectrum disorders. The study, published in Molecular Autism, explains how […] February 21, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 9 Nov 2017 Meet the Spin-Out Queen Taking on Neurological Diseases Mary Kerr, CEO of NeRRe and Managing Director of KanDy, told us how its approaches could change the face of therapies for neuronal hypersensitivity and women’s health indications. Mary Kerr’s career has taken her through the rigorous world of big pharma, which she says gave her “the skillset… the development, the exposure and the opportunity to work […] November 9, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 30 Oct 2017 French Biotech Closes €19M IPO to Treat Narcolepsy and Alzheimer’s Theranexus debuts on Euronext Paris raising €19.6M that will support the development of its pipeline of CNS drugs for narcolepsy, Parkinson’s, Alzheimer’s and neuropathic pain. Theranexus, based in Lyon, starts trading on Euronext Paris today. The company starts off with a market cap of €47.5M after closing a €19.6M IPO. With the money raised, the company […] October 30, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 14 Sep 2017 New Dutch Spin Out will Treat Stroke with RNA Therapy ProQR has spun out Amylon Therapeutics, a company that will treat central nervous system disorders with a lead candidate based on RNA technology. Amylon Therapeutics, a brand new spin-out from RNA company ProQR, has announced its first seed investment round. The funds, of an undisclosed amount, will help the new company kick off the development of its drug candidates. Based in Leiden, Amylon […] September 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2017 Austrian Researchers build an improved Mini-Brain to support Psychiatry Researchers from Austria and the UK have made new advances in engineering brain-like structures. These lab-grown organoids mimic important functions of the real thing and could help improve understanding of mental illness and test new therapies. The Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna is a pioneer of brain […] June 2, 2017 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 26 May 2017 UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy UPDATE (26/05/2017): GW has released more positive results in The New England Journal of Medicine demonstrating that Epidiolex dramatically reduces convulsive seizures in children with Dravet syndrome. The results have primed the drug for its NDA submission to the FDA and led some to forecast blockbuster success. Original Publication 30/03/2016 GW Pharmaceuticals (UK) has announced positive results […] May 26, 2017 - 4 minutesmins - By Ekaterina Perets Share WhatsApp Twitter Linkedin Email